Onconetix

Onconetix P/B

The P/B (Price-to-Book Ratio) of Onconetix (ONCO) as of Nov 4, 2026 is 0.08. In the previous year, P/B (Price-to-Book Ratio) was 0.13 — a change of -39.04% (lower).

P/B

0.08

YoY

-39.04%

Last updated:

P/B (Price-to-Book Ratio) of Onconetix is 2025 0.08 . P/B (Price-to-Book Ratio) of Onconetix was 2024 0.13 . It decreases by -39.04% lower compared to the previous year.

The Onconetix P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2019
0.20 USD
Jan 1, 2020
0.25 USD
Jan 1, 2021
0.83 USD
Jan 1, 2022
0.05 USD
Jan 1, 2023
-0.21 USD
Jan 1, 2024
0.13 USD
Jan 1, 2025
0.08 USD
The Onconetix P/B history
YEARP/BYoY
0.08-39.04%
0.13-158.29%
-0.21-499.64%
0.05-93.54%
0.83+227.24%
0.25+26.72%
0.20—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Onconetix Stock analysis

What does Onconetix do? Blue Water Biotech, Inc. generates revenue through the development and licensing of transformative vaccine candidates. The company focuses on a streptococcus pneumonia vaccine candidate targeting acute otitis media in children and pneumonia in the elderly, alongside a universal flu vaccine designed to protect against all virulent strains. It also licenses a norovirus S&P nanoparticle VLP platform from Cincinnati Children’s Hospital Medical Center to develop vaccines for diseases like Marburg and monkeypox. Collaborations with the University of Texas Health Science Center in San Antonio (UT Health) support the development of a Chlamydia vaccine candidate. The primary buyers of Blue Water Biotech's products are global health organizations and pharmaceutical companies seeking innovative vaccine solutions. The company's portfolio targets high-need segments including pediatric infectious diseases, elderly respiratory health, and emerging viral threats such as Marburg and monkeypox. Licensing agreements with institutions like Cincinnati Children’s Hospital Medical Center and UT Health provide key revenue streams through technology transfer and co-development partnerships. Blue Water Biotech's business model centers on R&D-driven innovation, with revenue derived from vaccine development milestones, licensing fees, and potential future sales of approved vaccines. The company's focus on addressing significant global health challenges through transformational therapies positions it to secure partnerships with healthcare institutions and pharmaceutical firms interested in expanding their vaccine portfolios. Onconetix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Onconetix stock

P/B (Price-to-Book Ratio) of Onconetix is 0.08 in 2025.

P/B (Price-to-Book Ratio) of Onconetix changed from 0.13 to 0.08, representing a -39.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Onconetix since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Onconetix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Onconetix

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Onconetix